

March 28, 2024

Subject: Invitation to 2024 Annual General Meeting of Shareholders

Dear Shareholders of Inter Pharma Public Company Limited

Attachment:

1. A copy of the Minute of the 2023 Annual General Meeting of Shareholders
2. QR Code Downloading Procedures for Annual Report 2023 (Form 56-1 One Report)
3. Capital Increase Report Form (F 53-4)
4. Profiles and working experiences of the candidates nominated for election as the directors in place of those who retire by rotation
5. Profiles of the Auditors proposed for the year 2024
6. Profiles of the Independent Directors who has been proposed to be proxies of shareholders
7. Proxy Forms (Form A, Form B, and Form C)
8. Article of Association of the Company only to the extent relating to the Shareholders Meeting
9. Guidelines for attending the AGM through E-Meeting and the appointment of Proxies
10. Form Registration for attending the 2024 AGM through E-Meeting
11. Requisition Form for 56-1 One Report 2023
12. Personal Data Protection Notice for the Shareholder Meeting
13. Quidlab E-Meeting & Voting System User's Manual Conferencing Option

The Board of Directors' Meeting of Inter Pharma Public Company Limited ("the Company") No. 1/2024 held on February 29, 2024 passed a resolution to call for the 2024 Annual General Meeting of Shareholders through E-Meeting as a sole meeting format in accordance with the criteria stipulated by the relevant laws on Friday, April 26, 2024, at 14.00 hrs., broadcast live at the conference room No. 140/9 ITF Tower, 9 Floor, Silom Road, Suriyawongse, Bangrak, Bangkok 10500, with the agenda as follows:

Agenda 1: To certify the Minutes of the 2023 Annual General Meeting of Shareholders

Objective and Rationale: The Company prepares the minutes of the 2023 Annual General Meeting of Shareholders on April 27, 2023, submitted to the Stock Exchange of Thailand on May 10, 2023, and publicly disclosed on the Company's website www.interpharma.co.th, details as per **Attachment No. 1.**

Opinion of the Board of Directors: The Board of Directors considered that the minutes of the 2023 Annual General Meeting of Shareholders on April 27, 2023 were recorded correctly and truthfully. Therefore, it was deemed appropriate to propose that the Annual General Meeting of Shareholders to certify the Minutes of the 2023 Annual General Meeting of Shareholders.

Voting: This agenda must be certified by a majority vote of the shareholders who attend the meeting and have the right to vote.

Agenda 2: To acknowledge the Company's performance for the year 2023 and approve the annual financial statements ended December 31, 2023

Objective and Rationale: According to Section 112 of the Public Limited Company Act B.E. 2535 (1992) (including any amendment thereto) and Article 46 of the Company's Articles of Association, the Company has to prepare the Financial Statements as of the date ending the Company's accounting period for submission to the shareholders' meeting for consideration and approval.

Opinion of the Audit Committee: The Audit Committee Meeting No. 1/2024 held on February 29, 2024 has reviewed the reports of the Company and its subsidiaries' operating results for the year 2023 and deemed that they were accurate and contained all essential information. The Audit Committee also reviewed the Company and the subsidiaries' financial statements for the year ended December 31, 2023 as proposed by the Company's auditor and found that they were accurate and credible, as well as disclosed adequate information.

Opinion of the Board of Directors: The Board of Directors deemed it appropriate to propose to the Annual General Meeting of Shareholders to acknowledge the Company's performance for the year 2023 and approve the Financial Statements for the year ended December 31, 2023, as duly audited and certified by the auditor from EY Office Limited and reviewed by the Audit Committee. Details are as shown in the Annual Registration Statement /Annual Report 2023 (Form 56-1 One Report 2023) (downloaded from the QR Code in **Attachment No. 2.**)

The summary of the Company's financial status and performance during the year 2023 is as follows:

		Consolidated Financial Statement		Separate Financial Statement	
		2023	2022 (Restated)	2023	2022
Total Assets	(Million Baht)	2,952.37	3,090.31	2,239.25	2,380.83
Total Liabilities	(Million Baht)	834.64	973.86	323.58	458.87
Total Revenue	(Million Baht)	1,798.77	1,534.45	619.91	623.24
Profit (Loss) for the year*	(Million Baht)	58.90	127.28	58.20	101.66
Earning (Loss) per share	(Baht :Share)	0.136	0.363	0.156	0.311

*Profit for the year: Equity Holders of the Company

Voting: This agenda must be certified by a majority vote of the shareholders who attend the meeting and have the right to vote.

Agenda 3: To consider and approve the dividend payment and allocation of legal reserve for operating results of the year 2023

Objective and Rationale: According to Section 115 of the Public Limited Company Act B.E. 2535 (1992) (as amended) and Article 51 of the Company's Articles of Association, provide that no dividends shall be paid other than out of profits. The Company's policy is to pay dividends at the rate of not less than 50 percent of the net profits after deducting the legal reserves and, provided that dividend payment will be subjected to the Company's cash flow, investment plan, conditions and terms of agreements to which the Company is bound, as well as the necessity and other appropriateness in the future.

And according to Section 116 of the Public Limited Company Act B.E. 2535 (1992) (including any amendment thereto) and Clause 53 of the Company's Articles of Association, the Company must allocate part of the annual net profit as reserve fund in an amount not less than five percent of the annual net profit less the sum of accumulated loss brought forward (if any) until the reserve fund amounts to be not less than ten percent of the registered capital.

Opinion of the Board of Directors: The Board of Directors deemed it appropriate to propose to the Annual General Meeting of Shareholders to approve the allocation of net profit for the year 2023 in the amount of 2.91 Million Baht as the Company's legal reserve and approve the payment of dividends in the stock dividends and cash and allocation of legal reserves for operating results in 2023, details are as follows:

1. The dividend payment in form of ordinary shares of the Company from the retained earnings of not exceeding 232,825,328 shares at par value of Baht 0.50 per share to the shareholders at the ratio of 8 existing share to 5 stock dividend, totaling of not exceeding Baht 116,412,664 or equivalent to the dividend payment at the rate of Baht 0.3125 per share.

In case that the shareholders has share fraction derived from the allocation of stock dividend, the Company will pay such shareholder for fraction in cash at the rate of Baht 0.3125 per share.

2. The dividend payment in cash to shareholders at the rate of Baht 0.0348 per share, totalling not exceeding Baht 12,963,714.2352 (to accommodate for 10 percent withholding tax of assessable income pursuant to Section 50 (2) (Jor) of the Thai Revenue Code for the dividend's receiver).

Including the dividend payment in items 1. and 2. above is at the rate of Baht 0.3473 per share, totaling not exceeding Baht 129,376,378.2352. Such dividend payment is in accordance with the Company's dividend payment policy, individual shareholders may apply for dividend tax credit.

The Board of Directors has set the Record Date on May 8, 2024 to determine the name of shareholders who are entitled to receive the dividend and to pay the dividend on May 24, 2024.

The comparison of dividend payments during the past 3 years is detailed as follows:

Description	2023 (proposed year)	2022	2021
Dividend Payment (Million Baht)	129.376	67.05	-
● Dividend for year (Baht : share)	0.3473	0.18	-
○ Stock Dividend Payout Ratio (Existing Share : Stock Dividend)	8 : 5	-	-
○ Stock Dividend Payout Ratio (Baht : Share)	0.3125	-	-
○ Cash Dividend Payout Ratio (Baht : Share)	0.0348	0.18	-
Dividend Payment to Net Profit Ratio (%)	62.12	69.44	-

Voting: This agenda must be certified by a majority vote of the shareholders who attend the meeting and have the right to vote.

Agenda 4: To consider and approve the capital decrease of the Company's registered capital by means of canceling the unissued registered shares of the Company and the amendment to Article 4 of the Company's Memorandum of Association to comply with the decrease of the Company's registered capital

Objective and Rationale: According to Section 136 of Public Limited Companies Act, B.E. 2535 (1992) (as amended), the Company may issue new shares when all shares have been sold and fully paid-up, except for the remaining shares which are issued for the exercise of warrants reserved for the exercise of the warrant to subscribe for the shares. Since the Company plans to increase its registered capital, to allocate reserve for exercise the rights of the warrants to purchase ordinary shares of the Company No. 2 (IP-W2). At present the Company has a registered capital of 243,363,711.50 Baht divided into 486,727,423 shares with a par value of 0.50 Baht per share, and paid-up capital of 186,260,262 Baht divided into 372,520,524 shares with a par value of 0.50 Baht per share, Thus the Company has the unissued registered shares of the Company in the amount 21,077,208 shares, which consists:

- (1) Reserve for the exercise of the warrants to purchase the Company's ordinary shares No. 1 (IP-W1) of 21,076,768 shares
- (2) Reserve for the remaining shares reserved for exercise the rights of the warrants to purchase ordinary shares of the Company No. 2 (IP-W2) of 440 shares

The Company shall reduce its registered capital by canceling 21,077,208 unpaid-up ordinary shares and the amendment of Article 4 of the Company's Memorandum of Association to comply with the decrease of the Company's registered capital.

Opinion of the Board of Directors: The Board of Directors deemed it appropriate to propose to the Annual General Meeting of Shareholders to consider and approve of the capital decrease of Baht 10,538,604 from the registered capital of Baht 243,363,711.50 to Baht 232,825,107.50 by canceling 21,077,208 shares unpaid-up ordinary shares with a par value of Baht 0.50 per share to allocate reserve for exercise the rights of the warrants to purchase ordinary

shares of the Company No. 1 (IP-W1) of 21,076,768 shares and the remaining shares reserved for exercise the rights of the warrants to purchase ordinary shares of the Company No. 2 (IP-W2) of 440 shares and approve the amendment of Article 4 of the Company's Memorandum of Association to comply with the decrease of the Company's registered capital as follows;

“Article 4. Registered capital	232,825,107.50 Baht	(Two hundred thirty-two million eight hundred twenty-five thousand one hundred seven Baht and fifty Satang)
Divided into	465,650,215 shares	(Four hundred sixty-five million six hundred fifty thousand two hundred fifteen shares)
Par value	0.50 Baht	(Fifty Satang)
Divided into		
Ordinary shares	465,650,215 shares	(Four hundred sixty-five million six hundred fifty thousand two hundred fifteen shares)
Preferred shares	- None –	-”

In addition, the Board of Directors deemed it appropriate to propose to the Annual General Meeting of Shareholders the authorization to the authorized directors of the Company in accordance with the Company's affidavit or any person authorized by such authorized directors to have the authority to undertake any necessary actions for the registration of the amendment of the Memorandum of Association as approved until completion.

Voting: This agenda must be approved by a vote of not less than three-fourths of the total number of votes of shareholders attending the meeting who are entitled to vote.

Agenda 5: To consider and approve the capital increase of the Company's registered capital and the amendment to Article 4 of the Company's Memorandum of Association to comply with the increase of the Company's registered capital

Objective and Rationale: The Company would like to approve the capital increase of the Company Baht 145,562,257.50 from the former registered capital of Baht 232,825,107.50 to Baht 378,387,365 by issuing 291,124,515 newly issued ordinary shares with a par value of Baht 0.50 to accommodate the stock dividend payment of 232,825,328 shares and reserve the adjustment for exercise the rights of the warrants to purchase ordinary shares of the Company No. 2 (IP-W2) of 58,299,187 shares and approve the amendment of Article 4 of the Company's Memorandum of Association to comply with the increase of the Company's registered capital.

Opinion of the Board of Directors: The Board of Directors deemed it appropriate to propose to the Annual General Meeting of Shareholders to consider and approve the capital increase of the Company of Baht 145,562,257.50 from the former registered capital of Baht 232,825,107.50 to Baht 378,387,365 by issuing 291,124,515 newly issued ordinary shares with a par value of Baht 0.50 to accommodate the stock dividend payment of 232,825,328 shares and reserve the adjustment for exercise the rights of the warrants to purchase ordinary shares of the Company No.

2 (IP-W2) of 58,299,187 shares and approve the amendment of Article 4 of the Company's Memorandum of Association to comply with the increase of the Company's registered capital as follows;

“Article 4. Registered capital	378,387,365	Baht	(Three hundred seventy- eight million three hundred eighty-seven thousand three hundred sixty-five Baht)
Divided into	756,774,730	shares	(Seven hundred fifty-six million seven hundred seventy- four thousand seven hundred thirty shares)
Par value	0.50	Baht	(Fifty Satang)
Divided into			
Ordinary shares	756,774,730	shares	(Seven hundred fifty-six million seven hundred seventy- four thousand seven hundred thirty shares)
Preferred shares	- None –		-”

In addition, the Board of Directors deemed it appropriate to propose to the Annual General Meeting of Shareholders the authorization to the authorized directors of the Company in accordance with the Company's affidavit or any person authorized by such authorized directors to have the authority to undertake any necessary actions for the registration of the amendment of the Memorandum of Association as approved until completion.

Voting: This agenda must be approved by a vote of not less than three-fourths of the total number of votes of shareholders attending the meeting who are entitled to vote.

Agenda 6: To consider and approve the allocation of newly issued ordinary shares of the Company

Objective and Rationale: According to the capital increase plan in Agenda 5 above, the Company will allocate not more than 291,124,515 newly issued ordinary shares at a par value of 0.50 Baht per share, to accommodate the stock dividend payment and reserve the adjustment for exercise the rights of the warrants to purchase ordinary shares of the Company No. 2 (IP-W2).

Opinion of the Board of Directors: The Board of Directors deemed it appropriate to propose to the Annual General Meeting of Shareholders to consider and approve the allocation of not more than 291,124,515 newly issued ordinary shares with a par value of Baht 0.50 to accommodate the stock dividend payment of 232,825,328 shares and reserve the adjustment for exercise the rights of the warrants to purchase ordinary shares of the Company No. 2 (IP-W2) of 58,299,187 shares and deemed it appropriate to propose to the Annual General Meeting of Shareholders to consider and approve the Company will assign the Board of Directors and/or Chief Executive Officer and/or persons assigned by the Board of Directors and/or Chief Executive Officer are authorized to determine and amend the conditions and details related to the issuance and allocation of the newly issued ordinary shares.

Voting: This agenda must be certified by a majority vote of the shareholders who attend the meeting and have the right to vote.

Agenda 7: To consider and approve the appointment of directors replacing those due to retire by rotation

Objective and Rationale: According to Section 71 of the Public Limited Company Act B.E. 2535 (1992) (including any amendment thereto) and Clause 21 of the Company's Articles of Association, stipulates that in every annual general meeting of shareholders one third (1/3) of the total number of Directors shall vacate office. If the number of Directors vacating office cannot be exactly divided by one-third (1/3), the number that is similar to one-third (1/3) shall be used. However, Directors who due to retire can be re-elected to return to the position again.

The 2024 Annual General Meeting of Shareholders, there are 3 directors who have completed their term of office as follows:

- | | |
|-------------------------------------|----------------------|
| 1. Professor Dr. Sansanee Chaiyaroj | Independent Director |
| 2. Dr. Nat Ativitavas | Director |
| 3. Dr. Yuttana Suwannachot | Director |

The Company provides an opportunity for shareholders to propose agendas and nominate candidates to be elected as directors during November 1, 2023 – December 31, 2023, in which there were no shareholders proposing agendas and names of persons to be considered for election as a director.

Opinion of the Nomination and Remuneration Committee: The Nomination and Remuneration Committee (excluding the stakeholders) has carefully reviewed before presenting to the Board of Directors and to propose to the Annual General Meeting of Shareholders for election directors, considering the qualifications of directors as specified in the relevant laws, the Company's regulations, proportion and qualification of Independent Directors according to the definition of Independent Director of the Company, as well as knowledge, capabilities and experience that are useful to the Company's business. The Nomination and Remuneration Committee deemed it appropriate to propose the appointment of Professor Dr. Sansanee Chaiyaroj, Dr. Nat Ativitavas, and Dr. Yuttana Suwannachot to return to serve as Directors for another term. The Nomination and Remuneration Committee considered that all candidates nominated have all qualifications as specified by relevant regulations and suitable for the business, and the candidates nominated as independent directors are fully qualified in accordance with the law and regulations relating to independent directors and are able to provide opinions independently. Profiles and working experiences of the candidates nominated for election as the directors in place of those who retire by rotation in **Attachment No. 4.**

Opinion of the Board of Directors: (excluding stakeholders) considered the list of nominated persons, which have been carefully screened and considered by the Nomination and Remuneration Committee, and deemed it appropriate to propose to the Annual General Meeting of Shareholders to appoint 3 directors, namely Professor Dr. Sansanee Chaiyaroj, Dr. Nat Ativitavas, and Dr. Yuttana Suwannachot to return to serve as Directors for another

term. The Board of Directors considered that the candidates nominated as an Independent Directors have all qualifications as specified by relevant regulations and are able to provide opinions independently.

Voting: This agenda must be certified by a majority vote of the shareholders who attend the meeting and have the right to vote.

Agenda 8: To consider and approve the remuneration of directors for the year 2024

Objective and Rationale: According to Section 90 of the Public Company Limited Act B.E. 2535 (1992) (as amended) and Article 26 of the Company’s Articles of Association, Directors are eligible for remuneration in forms of rewards, meeting allowance, gratuity, bonus or other benefit according to the resolution of the Shareholders’ Meeting by not less than two-thirds (2/3) of the total number of vote of the shareholders attending the meeting and having the right to vote.

Opinion of the Nomination and Remuneration Committee: The Nomination and Remuneration Committee conducted a survey on remuneration for the Board of Directors and sub-committees for the year 2024, considering the suitability from the scope of duties and responsibilities, the responsibilities and performance of the Board of Directors and each sub-committee, business expansion, the Company’s performance and comparative information with other companies in the same industry with similar size and nature of the business and considered appropriate to maintain the remuneration of the Board of Directors and sub-committees, including monthly remuneration and meeting allowance at the same rate as year 2023.

Opinion of the Board of Directors: The Board of Directors deemed it appropriate to propose to the Annual General Meeting of Shareholders to approve the remuneration of the Board of Directors and sub-committees for the year 2024 (proposed year) at the same rate as year 2023 as proposed by the Nomination and Remuneration Committee who had taken into consideration various factors and criteria as follows:

Position	2024 (proposed year)	2023
Monthly remuneration (person : month) For non-executive directors <ul style="list-style-type: none"> ● Chairman ● Director 	30,000 Baht 20,000 Baht	30,000 Baht 20,000 Baht
Meeting Allowance For non-executive director (Baht : time) (pay only to meeting attendee) <u>Board of Directors</u> <ul style="list-style-type: none"> ● Chairman ● Director 	20,000 Baht 15,000 Baht	20,000 Baht 15,000 Baht

Position	2024 (proposed year)	2023
<u>Audit Committee</u>		
● Chairman	22,500 Baht	22,500 Baht
● Director	15,000 Baht	15,000 Baht
<u>Nomination and Remuneration Committee</u>		
● Chairman	15,000 Baht	15,000 Baht
● Director	10,000 Baht	10,000 Baht
<u>Corporate Governance and Sustainable Development Committee</u>		
● Chairman	15,000 Baht	15,000 Baht
● Director	10,000 Baht	10,000 Baht
<u>Risk Management Committee</u>		
● Chairman	15,000 Baht	15,000 Baht
● Director	10,000 Baht	10,000 Baht

For the policy of paying bonuses to independent directors and non-executive directors (whole board), the Company pays no more than 0.5% of the announced dividend amount. The monthly remuneration, meeting allowance and other benefits, the total amount must not exceed 4 Million Baht. By assigning the Board of Directors or the person assigned by the Board of Directors to consider and allocate bonuses to independent directors and non-executive directors.

The details of the remuneration of each Director for 2023 are presented in Form 56-1 One Report 2023 under section 8 Corporate Governance Milestone, sub-section 8.1.2 Meeting Attendance and Individual Directors' Compensation.

Voting: This agenda must be approved by a vote of not less than two-thirds of the total number of votes of the shareholders who attend the meeting and have the right to vote.

Agenda 9: To consider and approve the appointment auditors and audit fee for the year 2024

Objective and Rationale: According to Section 120 of the Public Company Limited Act B.E. 2535 (1992) (as amended), which stipulates that the Annual General Meeting of Shareholders shall appoint auditors and determine audit fees every year. In appointing the auditor, the same auditor may be reappointed.

Opinion of the Audit Committee: The Audit Committee has considered and approved the selection of auditors from EY Office Limited to be the auditors of the Company and its subsidiaries for the year 2024, which has been the same auditor for the fourth consecutive year. EY Office Limited has satisfactorily performed its duties to the Company in accordance with the auditing standards and provided useful opinions useful opinions to the Company and independent and agreed that the audit fee proposed by EY Office Limited was appropriate, when compared to the scope of service and workload.

Opinion of the Board of Directors: With careful consideration Audit Committee, The Board of Directors deemed it appropriate to propose to the Annual General Meeting of Shareholders to appoint auditors from EY Office Limited, which is the same auditor as the Company's subsidiaries, whereby one of the following auditors will be appointed as the auditor of the Company for the year 2024.

- | | | |
|----|--------------------------------|---|
| 1. | Ms. Siriwan Nitdamrong, | Certified Public Accountant No. 5906 and / or |
| 2. | Ms. Kamonthip Lertwitworathep | Certified Public Accountant No. 4377 and / or |
| 3. | Ms. Satida Ratananurak | Certified Public Accountant No. 4753 and / or |
| 4. | Mrs. Sarinda Hirunprasurtwutti | Certified Public Accountant No. 4799 |

All above four auditors are qualified and has no relationship or any conflict of interest with the Company, its subsidiaries and associates, management, major shareholders or any person related to such person. Therefore, there is independence in auditing and express an opinion on the Company's financial statements, its subsidiaries and associates including the certified auditors as above, no auditors have performed the audit duties of the Company for more than the period specified in the relevant announcement. (Profiles of the Auditors proposed for the year 2024, Attachment No. 5).

The Board of Directors also deemed it appropriate to propose to the Annual General Meeting of Shareholders to approve the audit fees of the Company for the year 2024 (not include non-audit fee) as follows:

List of services	2024 (proposed year)	2023	Increase/(Decrease)
Audit fee of the Company	1,890,000	1,790,000	100,000

Voting: This agenda must be certified by a majority vote of the shareholders who attend the meeting and have the right to vote.

Agenda 10: To consider and approve the changes in the objectives of utilization of the increase capital form allotment ordinary shares to Private Placement

Objective and Rationale: According to the Extraordinary General Meeting of Shareholders No. 1/2022 on July 20, 2022, it was resolved to approve the allocation of 74,510,000 newly issued ordinary shares at the offering price of Baht 14 per share, a total of Baht 1,043,140,000. As of December 31, 2023, the Company has used the money from the increase capital in the amount of Baht 935,612,630 and remaining amount of Baht 107,527,370. In this regard, the Company wishes to request a change the objective of utilization of the increase capital form allotment ordinary shares to Private Placement, using the remaining amount of Baht 21,000,000 from use for LAB Pharmacy branches expansion to be used as working capital, because the expansion of drugstore branches will be operated by Drug Care Company Limited.

Opinion of the Board of Directors: The Board of Directors deemed it appropriate to propose to the Annual General Meeting of Shareholders to consider and approve the change of objective of utilization of the increase capital form

allotment ordinary shares to Private Placement from use for LAB Pharmacy branches expansion to be used as working capital. The changes can be summarized as follows

(Unit: Baht)

The purpose of funds utilization	Funds utilization plan	Actual spending as of December 31, 2023	Remaining as of December 31, 2023	After the change of purpose of the use of funds
1. Use for expansion a new business related to the current business	500,000,000	475,300,000	24,700,000	24,700,000
2. Use for investment on EU standard technology transfer for Eye Drop products of Inter Pharma's Ayutthaya Site Factory.	100,000,000	38,172,630	61,827,370	61,827,370
3. Use for investment in new business of cosmeceutical and effervescent tablets of Modern Pharma factory	50,000,000	50,000,000	-	-
4. Use for LAB Pharmacy branches expansion	100,000,000	79,000,000	21,000,000	-
5. Loan repayment	150,000,000	150,000,000	-	-
6. Use as working capital	143,140,000	143,140,000	-	21,000,000
Total	1,043,140,000	935,612,630	107,527,370	107,527,370

Voting: This agenda must be certified by a majority vote of the shareholders who attend the meeting and have the right to vote.

Agenda 11: To consider any other matters (if any)

The Company provides an opportunity for shareholders to propose agendas of the 2024 Annual General Meeting of Shareholders in advance during the period from November 1, 2023 to December 31, 2023, under the good corporate governance principles. However, no shareholders has proposed any agendas for the meeting.

Therefore, we would like to invite the shareholders to attend the 2024 Annual General Meeting of Shareholders on **Friday, April 26, 2024 at 14.00 hrs. via Electronic means (E-Meeting) only**. Shareholders can submit a registration form for a meeting via E-Meeting as per **Attachment No. 10** and identity verification documents to the Company by **April 23, 2024**. The company will open registration to attend the meeting via electronic media **on Friday, April 26, 2024 at 13.00 hrs.** until the meeting is adjourned.

The Company has published this invitation letter for the 2024 Annual General Meeting of Shareholders together with supporting documents and Proxy form; Form A, Form B and Form C which are available on the Company website at www.interpharma.co.th, section Investor Relation.

For shareholders who wish to appoint a proxy to attend and vote on their behalf in the meeting, please kindly complete and duly sign either Proxy Form A or Form B provided herewith as per **Attachment No. 7** or download them at www.interpharma.co.th and execute only one of the aforementioned forms. A shareholder who wishes to appoint an independent director of the Company to be a Proxy to attend and vote on behalf of shareholders whom of which is Clinical Professor Emeritus Udom Kachintorn, MD. and/or Mr. Kamtorn Sila-on information of the independent directors proposed by the Company to be the Shareholders' Proxies as per **Attachment No. 6** and submit the completed Proxy Form with the required documents to the Company in advance so that the Company receives them by **April 23, 2024**.

In addition, the shareholders can send questions related to the agenda of the 2024 Annual General Meeting of Shareholders or other important information prior to the meeting date via email or by post to the Company Secretary, Inter Pharma Public Company Limited at No. 140/9 ITF Tower 9 Floor, Silom Road, Suriyawong, Bangrak, Bangkok 10500 or e-mail: comsec@interpharma.co.th.

Yours sincerely,



(Dr. Trinnawat Thanitnithiphan)

Chief of Executive Officer

For more information, please contact:

Office of Company Secretary:

Tel. 02-634-0225 ext. 30